recombinant human fgf 19 Search Results


recombinant fgf19  (Gold Biotechnology Inc)
90
Gold Biotechnology Inc recombinant fgf19
Wild-type (WT) or mLipin-1KO (KO) mice were pair-fed either a control diet or an ethanol-containing diet for 10 days followed by single gavage of ethanol. ( A ) Representative Western analysis of liver Ac-NF-κB, NF-κB, p-IκBα and IκBα. ( B ) Relative liver protein levels of liver Ac-NF-κB, NF-κB, p-IκBα and IκBα. ( C ) Male C57/6J mice were treated by intraperitoneal injection 1 mg/kg mouse body weight of recombinant <t>FGF19</t> for six hours. Relative adipose mRNA levels of adiponectin. Relative liver mRNA of Cyp7a1. ( D ) Male intestinal FGF15 knock out (FGF15KO) mice and LOX littermates (WT) mice were fed chow diets. Relative adipose mRNA levels of adiponectin. Relative liver mRNA levels of Cyp7a1. ( E ) Male C57/6J mice were treated by intraperitoneal injection with 0.5 μg/g mouse body weight of recombinant human globular adiponectin (gAcrp) for three days. Relative ileum FGF15. Relative liver mRNA of Cyp7a1. Results are expressed as means ± SEM (n = 4–6 mice). Means without a common letter differ, P < 0.05.
Recombinant Fgf19, supplied by Gold Biotechnology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant fgf19/product/Gold Biotechnology Inc
Average 90 stars, based on 1 article reviews
recombinant fgf19 - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
recombinant human fgf19 protein  (R&D Systems)
94
R&D Systems recombinant human fgf19 protein
Conjugated BAs inhibited the FXR-FGF15 to induce hepatic BA synthesis. a Gene expression of FXR and FGF15 in ileum of mice fed HFD and 450 mg/Kg/day Pu-erh tea for 26 weeks. n = 8 individuals/group. b FXR and FGF15 protein expression level in ileum of mice fed HFD and 450 mg/Kg/day Pu-erh tea for 26 weeks. n = 3 individuals/group. c Gene expression of FXR and FGF15 in ileum of mice fed HFD and 225 mg/Kg/day theabrownin for 8 weeks. n = 8 individuals/group. d Serum FGF15 levels of mice fed HFD and 450 mg/Kg/day Pu-erh tea for 26 weeks. n = 8 individuals/group. e Serum <t>FGF19</t> levels of human subjects that received standard diet and 50 mg/Kg/day Pu-erh tea for 4 weeks. n = 13 individuals/group. f Hepatic mRNA expression levels of BA synthetic enzymes of mice fed HFD and 450 mg/Kg/day Pu-erh tea for 26 weeks. n = 8 individuals/group. g Hepatic mRNA expression levels of BA synthetic enzymes of mice fed HFD and 225 mg/Kg/day theabrownin for 8 weeks. n = 8 individuals/group. h Hepatic protein expression levels of BA synthetic enzymes of mice fed HFD and 450 mg/Kg/day Pu-erh tea for 26 weeks. n = 3 individuals/group. i IHC staining of hepatic BA synthetic proteins of mice fed HFD and 450 mg/Kg/day Pu-erh tea for 26 weeks (scale bar, 50 μm). The mRNA expression and protein expression were normalized to GAPDH and β-Actin, respectively. Data were expressed as mean ± SEM. Differences between data in mice and human were assessed by Mann–Whitney U test and Wilcoxon rank-sum test, respectively, * p < 0.05, # p < 0.005
Recombinant Human Fgf19 Protein, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human fgf19 protein/product/R&D Systems
Average 94 stars, based on 1 article reviews
recombinant human fgf19 protein - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
human fgf19  (R&D Systems)
94
R&D Systems human fgf19
Conjugated BAs inhibited the FXR-FGF15 to induce hepatic BA synthesis. a Gene expression of FXR and FGF15 in ileum of mice fed HFD and 450 mg/Kg/day Pu-erh tea for 26 weeks. n = 8 individuals/group. b FXR and FGF15 protein expression level in ileum of mice fed HFD and 450 mg/Kg/day Pu-erh tea for 26 weeks. n = 3 individuals/group. c Gene expression of FXR and FGF15 in ileum of mice fed HFD and 225 mg/Kg/day theabrownin for 8 weeks. n = 8 individuals/group. d Serum FGF15 levels of mice fed HFD and 450 mg/Kg/day Pu-erh tea for 26 weeks. n = 8 individuals/group. e Serum <t>FGF19</t> levels of human subjects that received standard diet and 50 mg/Kg/day Pu-erh tea for 4 weeks. n = 13 individuals/group. f Hepatic mRNA expression levels of BA synthetic enzymes of mice fed HFD and 450 mg/Kg/day Pu-erh tea for 26 weeks. n = 8 individuals/group. g Hepatic mRNA expression levels of BA synthetic enzymes of mice fed HFD and 225 mg/Kg/day theabrownin for 8 weeks. n = 8 individuals/group. h Hepatic protein expression levels of BA synthetic enzymes of mice fed HFD and 450 mg/Kg/day Pu-erh tea for 26 weeks. n = 3 individuals/group. i IHC staining of hepatic BA synthetic proteins of mice fed HFD and 450 mg/Kg/day Pu-erh tea for 26 weeks (scale bar, 50 μm). The mRNA expression and protein expression were normalized to GAPDH and β-Actin, respectively. Data were expressed as mean ± SEM. Differences between data in mice and human were assessed by Mann–Whitney U test and Wilcoxon rank-sum test, respectively, * p < 0.05, # p < 0.005
Human Fgf19, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human fgf19/product/R&D Systems
Average 94 stars, based on 1 article reviews
human fgf19 - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
recombinant human fgf  (R&D Systems)
96
R&D Systems recombinant human fgf
Conjugated BAs inhibited the FXR-FGF15 to induce hepatic BA synthesis. a Gene expression of FXR and FGF15 in ileum of mice fed HFD and 450 mg/Kg/day Pu-erh tea for 26 weeks. n = 8 individuals/group. b FXR and FGF15 protein expression level in ileum of mice fed HFD and 450 mg/Kg/day Pu-erh tea for 26 weeks. n = 3 individuals/group. c Gene expression of FXR and FGF15 in ileum of mice fed HFD and 225 mg/Kg/day theabrownin for 8 weeks. n = 8 individuals/group. d Serum FGF15 levels of mice fed HFD and 450 mg/Kg/day Pu-erh tea for 26 weeks. n = 8 individuals/group. e Serum <t>FGF19</t> levels of human subjects that received standard diet and 50 mg/Kg/day Pu-erh tea for 4 weeks. n = 13 individuals/group. f Hepatic mRNA expression levels of BA synthetic enzymes of mice fed HFD and 450 mg/Kg/day Pu-erh tea for 26 weeks. n = 8 individuals/group. g Hepatic mRNA expression levels of BA synthetic enzymes of mice fed HFD and 225 mg/Kg/day theabrownin for 8 weeks. n = 8 individuals/group. h Hepatic protein expression levels of BA synthetic enzymes of mice fed HFD and 450 mg/Kg/day Pu-erh tea for 26 weeks. n = 3 individuals/group. i IHC staining of hepatic BA synthetic proteins of mice fed HFD and 450 mg/Kg/day Pu-erh tea for 26 weeks (scale bar, 50 μm). The mRNA expression and protein expression were normalized to GAPDH and β-Actin, respectively. Data were expressed as mean ± SEM. Differences between data in mice and human were assessed by Mann–Whitney U test and Wilcoxon rank-sum test, respectively, * p < 0.05, # p < 0.005
Recombinant Human Fgf, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant human fgf/product/R&D Systems
Average 96 stars, based on 1 article reviews
recombinant human fgf - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier
fgf19 displacement assay recombinant human fgf19  (R&D Systems)
93
R&D Systems fgf19 displacement assay recombinant human fgf19
Conjugated BAs inhibited the FXR-FGF15 to induce hepatic BA synthesis. a Gene expression of FXR and FGF15 in ileum of mice fed HFD and 450 mg/Kg/day Pu-erh tea for 26 weeks. n = 8 individuals/group. b FXR and FGF15 protein expression level in ileum of mice fed HFD and 450 mg/Kg/day Pu-erh tea for 26 weeks. n = 3 individuals/group. c Gene expression of FXR and FGF15 in ileum of mice fed HFD and 225 mg/Kg/day theabrownin for 8 weeks. n = 8 individuals/group. d Serum FGF15 levels of mice fed HFD and 450 mg/Kg/day Pu-erh tea for 26 weeks. n = 8 individuals/group. e Serum <t>FGF19</t> levels of human subjects that received standard diet and 50 mg/Kg/day Pu-erh tea for 4 weeks. n = 13 individuals/group. f Hepatic mRNA expression levels of BA synthetic enzymes of mice fed HFD and 450 mg/Kg/day Pu-erh tea for 26 weeks. n = 8 individuals/group. g Hepatic mRNA expression levels of BA synthetic enzymes of mice fed HFD and 225 mg/Kg/day theabrownin for 8 weeks. n = 8 individuals/group. h Hepatic protein expression levels of BA synthetic enzymes of mice fed HFD and 450 mg/Kg/day Pu-erh tea for 26 weeks. n = 3 individuals/group. i IHC staining of hepatic BA synthetic proteins of mice fed HFD and 450 mg/Kg/day Pu-erh tea for 26 weeks (scale bar, 50 μm). The mRNA expression and protein expression were normalized to GAPDH and β-Actin, respectively. Data were expressed as mean ± SEM. Differences between data in mice and human were assessed by Mann–Whitney U test and Wilcoxon rank-sum test, respectively, * p < 0.05, # p < 0.005
Fgf19 Displacement Assay Recombinant Human Fgf19, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fgf19 displacement assay recombinant human fgf19/product/R&D Systems
Average 93 stars, based on 1 article reviews
fgf19 displacement assay recombinant human fgf19 - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier

Image Search Results


Wild-type (WT) or mLipin-1KO (KO) mice were pair-fed either a control diet or an ethanol-containing diet for 10 days followed by single gavage of ethanol. ( A ) Representative Western analysis of liver Ac-NF-κB, NF-κB, p-IκBα and IκBα. ( B ) Relative liver protein levels of liver Ac-NF-κB, NF-κB, p-IκBα and IκBα. ( C ) Male C57/6J mice were treated by intraperitoneal injection 1 mg/kg mouse body weight of recombinant FGF19 for six hours. Relative adipose mRNA levels of adiponectin. Relative liver mRNA of Cyp7a1. ( D ) Male intestinal FGF15 knock out (FGF15KO) mice and LOX littermates (WT) mice were fed chow diets. Relative adipose mRNA levels of adiponectin. Relative liver mRNA levels of Cyp7a1. ( E ) Male C57/6J mice were treated by intraperitoneal injection with 0.5 μg/g mouse body weight of recombinant human globular adiponectin (gAcrp) for three days. Relative ileum FGF15. Relative liver mRNA of Cyp7a1. Results are expressed as means ± SEM (n = 4–6 mice). Means without a common letter differ, P < 0.05.

Journal: Scientific Reports

Article Title: Myeloid Cell-Specific Lipin-1 Deficiency Stimulates Endocrine Adiponectin-FGF15 Axis and Ameliorates Ethanol-Induced Liver Injury in Mice

doi: 10.1038/srep34117

Figure Lengend Snippet: Wild-type (WT) or mLipin-1KO (KO) mice were pair-fed either a control diet or an ethanol-containing diet for 10 days followed by single gavage of ethanol. ( A ) Representative Western analysis of liver Ac-NF-κB, NF-κB, p-IκBα and IκBα. ( B ) Relative liver protein levels of liver Ac-NF-κB, NF-κB, p-IκBα and IκBα. ( C ) Male C57/6J mice were treated by intraperitoneal injection 1 mg/kg mouse body weight of recombinant FGF19 for six hours. Relative adipose mRNA levels of adiponectin. Relative liver mRNA of Cyp7a1. ( D ) Male intestinal FGF15 knock out (FGF15KO) mice and LOX littermates (WT) mice were fed chow diets. Relative adipose mRNA levels of adiponectin. Relative liver mRNA levels of Cyp7a1. ( E ) Male C57/6J mice were treated by intraperitoneal injection with 0.5 μg/g mouse body weight of recombinant human globular adiponectin (gAcrp) for three days. Relative ileum FGF15. Relative liver mRNA of Cyp7a1. Results are expressed as means ± SEM (n = 4–6 mice). Means without a common letter differ, P < 0.05.

Article Snippet: 12 week old male C57BL/6J mice were treated by intraperitoneal injection with 1 mg/kg mouse body weight of recombinant FGF19 (Gold Biotech, St. Louis, MO) in PBS or vehicle (PBS) and then sacrificed six hours later.

Techniques: Western Blot, Injection, Recombinant, Knock-Out

Conjugated BAs inhibited the FXR-FGF15 to induce hepatic BA synthesis. a Gene expression of FXR and FGF15 in ileum of mice fed HFD and 450 mg/Kg/day Pu-erh tea for 26 weeks. n = 8 individuals/group. b FXR and FGF15 protein expression level in ileum of mice fed HFD and 450 mg/Kg/day Pu-erh tea for 26 weeks. n = 3 individuals/group. c Gene expression of FXR and FGF15 in ileum of mice fed HFD and 225 mg/Kg/day theabrownin for 8 weeks. n = 8 individuals/group. d Serum FGF15 levels of mice fed HFD and 450 mg/Kg/day Pu-erh tea for 26 weeks. n = 8 individuals/group. e Serum FGF19 levels of human subjects that received standard diet and 50 mg/Kg/day Pu-erh tea for 4 weeks. n = 13 individuals/group. f Hepatic mRNA expression levels of BA synthetic enzymes of mice fed HFD and 450 mg/Kg/day Pu-erh tea for 26 weeks. n = 8 individuals/group. g Hepatic mRNA expression levels of BA synthetic enzymes of mice fed HFD and 225 mg/Kg/day theabrownin for 8 weeks. n = 8 individuals/group. h Hepatic protein expression levels of BA synthetic enzymes of mice fed HFD and 450 mg/Kg/day Pu-erh tea for 26 weeks. n = 3 individuals/group. i IHC staining of hepatic BA synthetic proteins of mice fed HFD and 450 mg/Kg/day Pu-erh tea for 26 weeks (scale bar, 50 μm). The mRNA expression and protein expression were normalized to GAPDH and β-Actin, respectively. Data were expressed as mean ± SEM. Differences between data in mice and human were assessed by Mann–Whitney U test and Wilcoxon rank-sum test, respectively, * p < 0.05, # p < 0.005

Journal: Nature Communications

Article Title: Theabrownin from Pu-erh tea attenuates hypercholesterolemia via modulation of gut microbiota and bile acid metabolism

doi: 10.1038/s41467-019-12896-x

Figure Lengend Snippet: Conjugated BAs inhibited the FXR-FGF15 to induce hepatic BA synthesis. a Gene expression of FXR and FGF15 in ileum of mice fed HFD and 450 mg/Kg/day Pu-erh tea for 26 weeks. n = 8 individuals/group. b FXR and FGF15 protein expression level in ileum of mice fed HFD and 450 mg/Kg/day Pu-erh tea for 26 weeks. n = 3 individuals/group. c Gene expression of FXR and FGF15 in ileum of mice fed HFD and 225 mg/Kg/day theabrownin for 8 weeks. n = 8 individuals/group. d Serum FGF15 levels of mice fed HFD and 450 mg/Kg/day Pu-erh tea for 26 weeks. n = 8 individuals/group. e Serum FGF19 levels of human subjects that received standard diet and 50 mg/Kg/day Pu-erh tea for 4 weeks. n = 13 individuals/group. f Hepatic mRNA expression levels of BA synthetic enzymes of mice fed HFD and 450 mg/Kg/day Pu-erh tea for 26 weeks. n = 8 individuals/group. g Hepatic mRNA expression levels of BA synthetic enzymes of mice fed HFD and 225 mg/Kg/day theabrownin for 8 weeks. n = 8 individuals/group. h Hepatic protein expression levels of BA synthetic enzymes of mice fed HFD and 450 mg/Kg/day Pu-erh tea for 26 weeks. n = 3 individuals/group. i IHC staining of hepatic BA synthetic proteins of mice fed HFD and 450 mg/Kg/day Pu-erh tea for 26 weeks (scale bar, 50 μm). The mRNA expression and protein expression were normalized to GAPDH and β-Actin, respectively. Data were expressed as mean ± SEM. Differences between data in mice and human were assessed by Mann–Whitney U test and Wilcoxon rank-sum test, respectively, * p < 0.05, # p < 0.005

Article Snippet: The reagents used in the animal study included TCA (J&K Scientific, 909688), TCDCA (Matrix Scientific, 100646), TUDCA (J&K Scientific, 496672), Z-Guggulsterone (BioChemPartner, BCP07472), Fexaramine (BioChemPartner, BCP15784) and Recombinant human FGF19 protein (R&D system, 969-FG/CF).

Techniques: Gene Expression, Expressing, Immunohistochemistry, MANN-WHITNEY

FXR-FGF15 and FXR-SHP regulated BA synthesis in alternative pathway. a Dominant BAs in liver and ileum of HFD fed mice gavaged with 225 mg/Kg/day theabrownin and 50 mg/Kg/day TCA, TCDCA, TUDCA respectively for 8 weeks. n = 8 individuals/group. b mRNA expression of ileal FXR, FGF15 and hepatic FXR, SHP and BA synthetic genes in HFD fed mice gavaged with 225 mg/Kg/day theabrownin and 50 mg/Kg/day TCA, TCDCA, TUDCA respectively for 8 weeks. n = 8 individuals/group. c Immunofluorescence staining of ileal FXR, FGF15 and hepatic FXR, SHP of HFD fed mice gavaged with 225 mg/Kg/day theabrownin and 50 mg/Kg/day TCA, TCDCA, TUDCA respectively for 8 weeks (scale bar, 50 μm). d Fifty micromole per liter of TCDCA and TUDCA inhibited protein expression of nuclear FXR in the human FHs 74 Int and L02 cell lines, and 50 μM of CDCA and TCA activated the expression of nuclear FXR in human FHs 74 Int and L02 cell lines and promoted expression of CYP27A1 and CYP7B1 in alternative pathway of bile acids synthesis. n = 3 individuals/group. e Immunofluorescence staining of FXR, FGF19 in FHs 74 Int cells supplied with 50 μM CDCA, CDCA coupled with 50 μM of TCDCA, CDCA coupled with 50 μM of TUDCA, and 50 μM of TCA for 24 h (scale bar, 100 μm). f Immunofluorescence staining of FXR, SHP in L02 cell lines supplied with 50 μM of CDCA, CDCA coupled with TCDCA, CDCA coupled with TUDCA and TCA for 24 h (scale bar, 50 μm). g The mRNA expression of ileal FXR, FGF15 and hepatic BA synthetic genes in HFD fed mice gavaged with 225 mg/Kg/day theabrownin, theabrownin coupled with 100 mg/Kg/day fexaramine for 8 weeks. n = 8 individuals/group. h The mRNA expression of ileal FXR, FGF15 and hepatic BA synthetic genes in HFD fed mice gavaged with 225 mg/Kg/day theabrownin, theabrownin coupled with 50 μg/Kg/day recombinant FGF19 protein by intraperitoneal injection for 8 weeks. n = 8 individuals/group. The mRNA expression was normalized to GAPDH. Protein expression was normalized by β-Actin or Lamin B1. Data were expressed as mean ± SEM. Differences between data were assessed by the Mann–Whitney U test, * p < 0.05, # p < 0.005

Journal: Nature Communications

Article Title: Theabrownin from Pu-erh tea attenuates hypercholesterolemia via modulation of gut microbiota and bile acid metabolism

doi: 10.1038/s41467-019-12896-x

Figure Lengend Snippet: FXR-FGF15 and FXR-SHP regulated BA synthesis in alternative pathway. a Dominant BAs in liver and ileum of HFD fed mice gavaged with 225 mg/Kg/day theabrownin and 50 mg/Kg/day TCA, TCDCA, TUDCA respectively for 8 weeks. n = 8 individuals/group. b mRNA expression of ileal FXR, FGF15 and hepatic FXR, SHP and BA synthetic genes in HFD fed mice gavaged with 225 mg/Kg/day theabrownin and 50 mg/Kg/day TCA, TCDCA, TUDCA respectively for 8 weeks. n = 8 individuals/group. c Immunofluorescence staining of ileal FXR, FGF15 and hepatic FXR, SHP of HFD fed mice gavaged with 225 mg/Kg/day theabrownin and 50 mg/Kg/day TCA, TCDCA, TUDCA respectively for 8 weeks (scale bar, 50 μm). d Fifty micromole per liter of TCDCA and TUDCA inhibited protein expression of nuclear FXR in the human FHs 74 Int and L02 cell lines, and 50 μM of CDCA and TCA activated the expression of nuclear FXR in human FHs 74 Int and L02 cell lines and promoted expression of CYP27A1 and CYP7B1 in alternative pathway of bile acids synthesis. n = 3 individuals/group. e Immunofluorescence staining of FXR, FGF19 in FHs 74 Int cells supplied with 50 μM CDCA, CDCA coupled with 50 μM of TCDCA, CDCA coupled with 50 μM of TUDCA, and 50 μM of TCA for 24 h (scale bar, 100 μm). f Immunofluorescence staining of FXR, SHP in L02 cell lines supplied with 50 μM of CDCA, CDCA coupled with TCDCA, CDCA coupled with TUDCA and TCA for 24 h (scale bar, 50 μm). g The mRNA expression of ileal FXR, FGF15 and hepatic BA synthetic genes in HFD fed mice gavaged with 225 mg/Kg/day theabrownin, theabrownin coupled with 100 mg/Kg/day fexaramine for 8 weeks. n = 8 individuals/group. h The mRNA expression of ileal FXR, FGF15 and hepatic BA synthetic genes in HFD fed mice gavaged with 225 mg/Kg/day theabrownin, theabrownin coupled with 50 μg/Kg/day recombinant FGF19 protein by intraperitoneal injection for 8 weeks. n = 8 individuals/group. The mRNA expression was normalized to GAPDH. Protein expression was normalized by β-Actin or Lamin B1. Data were expressed as mean ± SEM. Differences between data were assessed by the Mann–Whitney U test, * p < 0.05, # p < 0.005

Article Snippet: The reagents used in the animal study included TCA (J&K Scientific, 909688), TCDCA (Matrix Scientific, 100646), TUDCA (J&K Scientific, 496672), Z-Guggulsterone (BioChemPartner, BCP07472), Fexaramine (BioChemPartner, BCP15784) and Recombinant human FGF19 protein (R&D system, 969-FG/CF).

Techniques: Expressing, Immunofluorescence, Staining, Recombinant, Injection, MANN-WHITNEY